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Duffy antigens are important in immunohematology. The 
reference allele for the Duffy gene (FY) is FY*02, which encodes 
Fyb. An A>G single nucleotide polymorphism (SNP) at coding 
nucleotide (c.) 125 in exon 2 defines the FY*01 allele, which 
encodes the antithetical Fya. A C>T SNP at c.265 in the FY*02 
allele is associated with weakening of Fyb expression on red blood 
cells (RBCs) (called FyX). Until recently, this latter change had 
not been described on a FY*01 background allele. Phenotype-
matched units were desired for a multi-transfused Vietnamese 
fetus with α-thalassemia. Genotyping of the fetus using a 
microarray assay that interrogates three SNPs (c.1-67, c.125, 
and c.265) in FY yielded indeterminate results for the predicted 
Duffy phenotype. Genomic sequencing of FY exon 2 showed that 
the fetal sample had one wild-type FY*01 allele and one new 
FY*01 allele with the c.265C>T SNP, which until recently had 
only been found on the FY*02 allele. Genotyping performed on 
samples from the proband’s parents indicated that the father 
had the same FY genotype as the fetus. Flow cytometry, which 
has been previously demonstrated as a useful method to study 
antigen strength on cells, was used to determine if this new 
FY*01 allele was associated with reduced Fya expression on the 
father’s RBCs. Median fluorescence intensity of the father’s RBCs 
(after incubation with anti-Fya and fluorescein-labeled anti-IgG) 
was similar to known FY*01 heterozygotes and significantly 
weaker than known FY*01 homozygotes. In conclusion, the 
fetus and father both had one normal FY*01 allele and one new 
FY*01 allele carrying c.265C>T. This new FY*01 allele, named 
FY*01W.01, is associated with weakened expression of Fya on 
RBCs. Immunohematology 2015;31:103–107.
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The Duffy blood group antigens, expressed on the Duffy 
antigen receptor for chemokines (DARC), are important, 
not only in the field of immunohematology where Duffy 
antibodies can cause transfusion reactions and hemolytic 
disease of the fetus and newborn, but also in the fields of 
anthropology, genetics, and disease, where the DARC protein 
is the receptor for the malarial parasite Plasmodium vivax.1 
The Duffy gene (FY) consists of two exons on chromosome 
1.2–4 The reference allele FY*02 (FY*B) encodes for Fyb, Fy3, 
Fy5, and Fy6. An A>G single nucleotide polymorphism (SNP) 
at coding nucleotide (c.) 125 in exon 2 defines the FY*01 
(FY*A) allele and results in an asparagine to glycine amino 
acid substitution in the protein (p.42 Asp>Gly) that results in 
expression of Fya on red blood cells (RBCs) (Table 1). There 
are several different mutations leading to the FYnull phenotype 
[Fy(a–b–), Fy:–3]. The most common is the FY*02N.01 allele; 
a t>c SNP at c.–67 located in a transcription factor binding site 
called a GATA box hinders binding of the transcription factor 
GATA-1, which results in loss of FY*02 expression on RBCs 
but not in tissues. Another prevalent Duffy variant is the C>T 
mutation at c.265 on the FY*02 allele, encoding a p.89 Arg 
to Cys amino acid substitution that causes weakening of Fyb, 
Fy3, and Fy6 expression (FyX).8–10 The microarray assay, HEA 
BeadChip™ (BioArray Solutions, Immucor, Norcross, GA), 
tests for these three notable SNPs to predict the Fy phenotype: 
Fya/Fyb (c.125G/A), GATA (c.–67t/c), and FyX (c.265C/T).11 A 
GATA box mutation has been described on the FY*01 allele 
that results in the Fy(a–b–) phenotype,12 but the c.265C>T 
(FyX) change had not been described on the FY*01 allele until 
recently.6,7
Flow cytometry has been shown to be a useful method 
for detecting differences in antigen strength (e.g., attributable 
to zygosity13) and has been used to study the expression of 
Table 1. Important nucleotide changes for different FY alleles
FY nucleotides
Promoter Exon 2
Allele –67 125 265 298 Comments
FY*02 (FY*B) t A C G Reference allele; Fyb
FY*02N.01 c A C G Fy(a–b–) erythroid cells only
FY*02W.01 t A T A Fy(b+w), FyX
FY*02W.02 t A T A c.145G>T ; Fy(b+w), FyX
FY*02W.03 t A C G c.266G>A; Fy(b+w)5
FY*02W.04 t A C G c.901C>T; Fy(b+w)5
FY*01 (FY*A) t G C G Fya
FY*01W.01 t G T G Fy(a+w)6
FY*01W.02 t G T A Fy(a+w)7
The allele in bold (FY*01W.01) is described in the text.
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Duffy antigens on RBCs of different phenotypes or of different 
ages.8,10,12,13–20 We describe the first reported example of an 
FY*01 allele with the c.265C>T (FyX) change; this allele 
was shown to be associated with weak expression of Fya as 
determined by flow cytometry.6
Case Report
The patient was a Vietnamese male fetus with 
α-thalassemia. A decision was made to provide the fetus 
with phenotype-matched RBC units but, because of multiple 
recent intrauterine transfusions, a genotype was needed to 
determine the fetus’ predicted phenotype. Molecular typing 
results  (HEA BeadChip, Immucor) indicated the following 
phenotype: C+ c– E– e+; K– k+ Kp(a–b+) Js(a–b+) Jk(a+b+); 
M– N+ S– s+; Lu(a–b+); Di(a–b+); Co(a+b–); Do(a+b+) Jo(a+) 
Hy+; LW(a+b–); SC:1,–2, but the Fya and Fyb results were 
“indeterminate.” Further molecular studies were performed on 
the fetal DNA to determine the Fy phenotype. Blood samples 




RBCs from the proband’s parents were typed with three 
different sources of anti-Fya and anti-Fyb (Immucor; Ortho 
Clinical Diagnostics, Raritan, NJ; American Red Cross, 
Washington, DC) by the indirect antiglobulin test (IAT). The 
grading scale included ½+ increments.21
Molecular Testing
Genomic DNA was isolated from mononuclear cells using 
a kit (QIAamp DNA Blood Mini Kit, Qiagen, Valencia, CA). 
Microarray testing was performed (HEA BeadChip, Immucor) 
with software (BASIS 3.3, BioArray Solutions Ltd., Warren, 
NJ). Amplification and Sanger sequencing of FY exon 2 was 
performed (BigDye Terminator Kit, Life Technologies, Grand 
Island, NY), and the resulting sequence was aligned to the 
consensus sequence (Sequencher 5.0, GeneCodes Corp., Ann 
Arbor, MI). Polymerase chain reaction–restriction fragment 
length polymorphism (PCR-RFLP) using BanI was used 
to interrogate FY*01/FY*02 (c.125G>A) as described by 
Tournamille et al.22
Flow Cytometry
A previously described flow cytometric method23 was used 
to study the strength of Fya on the proband’s parents’ RBCs; 
known genotyped and/or phenotyped donor or reagent RBCs 
were tested in parallel as controls. Briefly, 0.1 mL 5% washed 
RBCs were incubated with 0.2 mL undiluted polyclonal anti-
Fya (Immucor) for 30 minutes at 37°C, washed four times with 
0.85% (w/v) phosphate-buffered saline (PBS), then incubated 
with a dilution of a tagged antihuman globulin (FITC Fab 
anti-IgG, MP Biomedicals, Aurora, OH) for 30 minutes at 
room temperature, and washed once with 0.2% bovine serum 
albumin in PBS. Ten thousand events per sample were acquired 
by a flow cytometer (FACSort, BD Biosciences, San Jose, CA) 
using logarithmic amplification of forward scatter, side scatter, 
and green fluorescence. A gate was set on the forward versus 
side scatter dot plot to exclude debris, and the median green 
fluorescence of the gated events was obtained using software 
(CellQuest Pro, BD Biosciences). In addition to testing by flow 
cytometry, the RBCs incubated with anti-Fya were also tested 
by IAT (Anti-IgG, Ortho Clinical Diagnostics).
Results
Serologic Testing
The mother’s RBCs and the father’s RBCs both typed as 
Fy(a+b–); both reacted 4+ with all three sources of anti-Fya.
Molecular Testing
The molecular testing yielded an indeterminate predicted 
phenotype for the Duffy antigens on the proband’s sample. The 
microarray assay (HEA BeadChip, Immucor) results showed 
the fetal sample to be homozygous for c.125G, associated with 
the FY*01 (FY*A) phenotype, and heterozygous for c.265C>T 
change associated with the FY*02W.01 and FY*02W.02 alleles, 
while being homozygous for c.1-67t. Genomic sequencing of 
FY exon 2 confirmed the genotype results and determined that 
the c.298G>A SNP associated with the known FY*02W.01 and 
FY*02W.02 alleles was not present. The mother’s predicted 
phenotype by molecular typing was Fy(a+b–), and the sample 
was negative for the c.265C>T variant. The father’s sample, like 
that of the fetus, yielded indeterminate calls for Duffy antigens 
on the microarray assay. PCR-RFLP analysis showed the 
father’s sample to be homozygous for c.125G and heterozygous 
for c.265C/T, concordant with the molecular findings.
Flow Cytometry
Flow cytometry (median fluorescence) results of the 
controls [5 Fy(a+b–) donors who genotyped as homozygous 
for FY*01, 5 Fy(a+b+) donors who were obligate heterozygotes 
for FY*01, 3 Fy(a+b–) donors who genotyped as FY*01/
FY*02N.01 and thus were heterozygous for FY*01, and 2 
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Fy(a–b+) donors] and the two Fy(a+b–) parents of the fetus 
are shown in Figure 1. The median fluorescence results of 
the donors who were homozygous for FY*01 were clearly 
stronger than the median fluorescence results from the 
donors who were heterozygous, and two distinct groups were 
apparent. The father’s sample, with only one normal FY*01 
allele, gave results that fell clearly in the heterozygous group 
indicating that his other allele, the new FY*01 allele, coded for 
a weakened expression of Fya. The median fluorescence results 
of the mother’s sample fell in the gap between the homozygotes 
and the heterozygotes and could not be clearly distinguished 
as belonging to either group. The IAT results of all the Fy(a+) 
controls and the parents’ RBCs after incubation with anti-Fya 
were similar (3–3½+).
Discussion
The Duffy blood group system consists of five antigens 
(the antithetical Fya and Fyb; Fy3, Fy5, and Fy6) located on 
a multipass membrane glycoprotein known as DARC. The 
four common phenotypes, Fy(a+b–), Fy(a–b+), Fy(a+b+), and 
Fy(a–b–), are encoded by the FY*01, FY*02, and FY*02N.01 
alleles (Table 1). According to Howes et al.,1 the FY*01 allele 
is most common in Asia, the FY*02 allele is most common 
in Europe, and the FY*02N.01 (null) allele is most common 
in Africa; heterogeneity of all three alleles is greatest in the 
Americas. A small percentage (2–3%) of Caucasians have 
the FY*02W.01 allele that codes for weakened expression 
of Fyb, Fy3, and Fy6. This FyX phenotype is caused by the 
c.265C>T mutation that results in a p.89 Arg to Cys amino 
acid substitution; this change appears to cause reduced levels 
of DARC in the RBC membrane.8 The two alleles currently 
described with this change are FY*02W.01 and FY*02W.02. 
Both are associated with a second mutation at c.298G>A, 
which results in a p.100 Ala to Thr change; the FY*02W.02 
allele has an additional change at c.145G>T, which results in 
a p.49 Ala to Ser change. Two more recently described alleles 
in Caucasians, FY*02W.03 with a c.266G>A (p. 89 Arg to His) 
change and FY*02W.04 with a c.901C>T (p.303 Pro to Ala) 
change, also result in Fy(b+w) phenotypes.5
Although rare mutations in the FY*01 alleles have been 
described to cause null phenotypes,3,4,24 and there are reports 
of Southeast Asians with weak Fya on RBCs,25,26 until recently, 
no FY*01W alleles had been reported. In 2015, Lopez et al.7 
reported an Fy(a+b+) Australian Caucasian blood donor who 
was noted to have weak expression of Fya. This phenotype was 
shown to be associated with a new allele, FY*01W.02, which 
had both the c.265C>T and c.298G>A mutations (as seen 
with FY*02W.01 and FY*02W.02). In 2013, we reported, at an 
AABB meeting, a recently transfused Vietnamese patient who 
was found to have an unusual allele, FY*01W.01, with only the 
critical c.265C>T change.6 Because of recent transfusions, the 
proband could not be phenotyped to determine if this allele 
was associated with weak Fya expression, but his parents 
were willing to be tested. The Fy(a+b–) mother had a normal 
FY*01/FY*01 genotype, but the Fy(a+b–) father had the new 
allele with a normal allele (FY*01/FY*01W.01).
As the proband’s father typed 4+ with anti-Fya due to 
his FY*01 allele, it would have been difficult to determine the 
strength of Fya by manual titrations, which have been shown 
to be poor predictors of antigen strength (e.g., zygosity).13 Flow 
cytometry, however, has been used successfully to study Duffy 
antigens—for example, to demonstrate weak expression of Fyb, 
Fy3, and Fy6 on FyX phenotype RBCs8,10,15,17; to distinguish 
zygosity (e.g., FY*01/FY*01 vs. FY*01/FY*02N.01)12,13,15; 
and to study Duffy antigen expression on cultured erythroid 
cells or reticulocytes,14,16,18,20 after RBC storage and leukocyte 
reduction,19 and on ovalocytes.20 Our flow cytometry studies 
with known examples of FY*01 homozygotes and heterozy-
gotes showed clear differentiation between the two groups. 
The proband’s father’s RBCs gave results that clearly fell in the 
heterozygous group, thus indicating that the FY*01W.01 allele 
New FY*01 allele
Fig. 1. Median fluorescence (MF) results of RBCs from (1) five 
FY*01 homozygotes [phenotype = Fy(a+b–), genotype = FY*01/
FY*01, MF = 70–98], (2) two groups of FY*01 heterozygotes 
[phenotype = Fy(a+b+), genotype not determined (n = 5; MF = 
40–58), and phenotype = Fy(a+b–), genotype = FY*01/FY*02N.01 
(n = 3; MF = 40–50)], (3) two FY*01 negatives [phenotype = Fy(a–
b+), genotype not determined, MF = 5], (4) the proband’s father 
[phenotype = Fy(a+b–), genotype = FY*01/FY*01W.01, MF = 45], 
and (5) the proband’s mother [phenotype = Fy(a+b–), genotype = 
FY*01/FY*01, MF = 63].
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codes for weak expression of Fya. Interestingly, the proband’s 
mother’s RBCs gave results much weaker than any of the five 
FY*01/FY*01 homozygous controls (but still stronger than 
the eight FY*01 heterozygous controls). She may have an 
unknown variant FY*01 allele that codes for slightly weaker 
Fya expression.
In conclusion, we describe the first example of Fy(a+w). 
The presence of this phenotype was predicted by Tournamille 
et al.5 based on the description by Shimizu et al.25 of some Thai 
individuals with weak Fya. Unlike the alleles most commonly 
associated with Fy(b+w) and the other allele recently described 
with Fy(a+w), which have at least two mutations (c.265C>T and 
c.298G>A), the allele we are describing was only associated 
with one mutation (c.265C>T). This allele was discovered 
while performing molecular testing on samples from a 
recently transfused patient. Since the discovery of this allele, 
two more samples have been identified with the Fyx change 
on an FY*01 background at the Red Cross National Molecular 
Laboratory. Both samples were identified by indeterminate 
calls for the Duffy phenotype on microarray testing, much like 
the initial case report described here. The first, a female donor, 
race unknown, demonstrated both c.265C>T and c.298G>A 
changes on an FY*01 background (like the FY*01W.02 allele 
described by Lopez et al.7). The second case is a 49-year-old 
male patient, race unknown, with only the c.265C>T change 
located on the FY*01 background, specifically the FY*01W.01 
allele. As the use of molecular methods increases in the future, 
it is possible that more examples of FY*01 alleles associated 
with Fy(a+w) may be discovered.
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